Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03118674 · ClinicalTrials.gov registry record · Phase 2
Harvoni Treatment Porphyria Cutanea Tarda
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT03118674 is a Phase 2 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 23 participants.
The verdict
NCT03118674, a Phase 2 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
In the medical literature there case reports that Harvoni improves symptoms in patients with PCT. However, this has never been systematically tested. Therefore, the purpose of this study is to assess whether Harvoni alone is an effective therapy of active PCT in patients with Chronic Hepatitis C.
Interventions
- DRUG Harvoni
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2017-09-06 |
| Est. Completion | 2022-03-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03118674
The ClinicalTrials.gov registry entry for NCT03118674 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Harvoni is the first listed.
NCT03118674 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03118674 about?
NCT03118674 is a clinical study titled "Harvoni Treatment Porphyria Cutanea Tarda". In the medical literature there case reports that Harvoni improves symptoms in patients with PCT. However, this has never been systematically tested. Therefore, the purpose of this study is to assess whether Harvoni alone is an effective therapy of active PCT in patients with Chronic Hepatitis C.
What is the current status of trial NCT03118674?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2017-09-06. Estimated completion is 2022-03-04.
What interventions are being tested in trial NCT03118674?
The interventions under investigation include: Harvoni (DRUG).
Who is sponsoring clinical trial NCT03118674?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.